A repurposed drug could help improve response rates to immunotherapies
Maryam Mahdi | | Quick Read
Anti-fibrotic drug Setanaxib may have found a new use by boosting immunotherapy response rates, according to research published by scientists at the University of Southampton, UK (1). Despite exciting results in recent years, approximately 80 percent of cancer patients still fail to respond to immunotherapy (1).
The research group, led by Gareth Thomas, demonstrated that the drug helped improve immunotherapy response rates in mice by targeting cancer-associated fibroblasts (CAFs) – cells that Thomas’ previous work had shown help tumors evade immune recognition, increasing the risk of a poor response to immunotherapy.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.